Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) is focused on commercializing patent-protected disruptive healthcare technologies specifically designed to take leading roles for the treatment of a broad array of chronic, debilitating and life-threatening diseases including respiratory, autoimmune and cancer indications. The company anticipates building significant value for its shareholders while meeting its objectives. For further information, visit the Company’s web site at www.accentia.net.
- 17 years ago
QualityStocks
Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Profit Momentum Builds for Beeline Holdings Inc. (NASDAQ: BLNE) as Next-Gen Platform Accelerates
Beeline Holdings (NASDAQ: BLNE), a fast-growing digital mortgage platform redefining the path to homeownership, recently…
-
QualityStocksNewsBreaks – Why SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) Is ‘One to Watch’
Disseminated on behalf of SPARC AI Inc. and may include paid advertising. SPARC AI (CSE: SPAI) (OTCQB:…
-
QualityStocksNewsBreaks – BCII Enterprises Inc. (OTCID: BCII) Details Real-World Applications for Patent-Pending Coupon Token Architecture
BCII Enterprises (OTCID:BCII) today announced real-world applications for its patent-pending Coupon Token architecture, as detailed…